rimonabant
E275982
Rimonabant is a selective cannabinoid CB1 receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
All labels observed (1)
| Label | Occurrences |
|---|---|
| rimonabant canonical | 5 |
How this entity was disambiguated
This entity first appeared as the object of triple T2523541 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: rimonabant Context triple: [CB1 receptor, antagonist, rimonabant]
-
A.
CB1 receptor
The CB1 receptor is a G protein–coupled cannabinoid receptor in the brain and nervous system that mediates most of the psychoactive effects of cannabis.
-
B.
Sabu
Sabu is an alternative name for the Shabo language, a little-documented and possibly language-isolate tongue spoken by a small community in southwestern Ethiopia.
-
C.
Substiane
Substiane is a La Roche-Posay skincare line formulated to address loss of firmness, density, and comfort in mature or aging skin.
-
D.
THC
THC (tetrahydrocannabinol) is the primary psychoactive compound in cannabis responsible for the plant’s mind-altering effects.
-
E.
Acubens
Acubens is the traditional name of Alpha Cancri, a multiple star system in the constellation Cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: rimonabant Target entity description: Rimonabant is a selective cannabinoid CB1 receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
-
A.
CB1 receptor
The CB1 receptor is a G protein–coupled cannabinoid receptor in the brain and nervous system that mediates most of the psychoactive effects of cannabis.
-
B.
Sabu
Sabu is an alternative name for the Shabo language, a little-documented and possibly language-isolate tongue spoken by a small community in southwestern Ethiopia.
-
C.
Substiane
Substiane is a La Roche-Posay skincare line formulated to address loss of firmness, density, and comfort in mature or aging skin.
-
D.
THC
THC (tetrahydrocannabinol) is the primary psychoactive compound in cannabis responsible for the plant’s mind-altering effects.
-
E.
Acubens
Acubens is the traditional name of Alpha Cancri, a multiple star system in the constellation Cancer.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
CB1 receptor antagonist
ⓘ
anorectic drug ⓘ small molecule ⓘ synthetic cannabinoid ⓘ withdrawn drug ⓘ |
| adverseEffect |
anxiety
ⓘ
depression ⓘ dizziness ⓘ insomnia ⓘ nausea ⓘ suicidal ideation ⓘ |
| approvalYear | 2006 ⓘ |
| contraindication |
history of major depression
ⓘ
ongoing psychiatric disorders ⓘ |
| crossesBloodBrainBarrier | true ⓘ |
| developedAs |
anti-obesity drug
ⓘ
treatment for metabolic syndrome ⓘ |
| developedBy |
Sanofi-Aventis
ⓘ
linked to:
Sanofi
|
| hasATCCode | A08AX01 ⓘ |
| hasBioavailability | approximately 20% to 30% ⓘ |
| hasCASNumber | 168273-06-1 ⓘ |
| hasDrugBankID | DB06155 ⓘ |
| hasHalfLife | about 6 to 9 days ⓘ |
| hasIndication |
dyslipidemia
ⓘ
obesity ⓘ type 2 diabetes mellitus (adjunct treatment) ⓘ weight management in overweight patients with risk factors ⓘ |
| hasIUPACName | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ⓘ |
| hasLegalStatus | withdrawn from human use in most countries ⓘ |
| hasMechanismOfAction |
reduces endocannabinoid signaling in the central nervous system
ⓘ
selective CB1 receptor inverse agonist ⓘ |
| hasMolecularFormula | C22H21Cl3N4O ⓘ |
| hasMolecularWeight | 463.79 g/mol ⓘ |
| hasPubChemCID | 104850 ⓘ |
| hasTradeName |
Acomplia
ⓘ
Zimulti ⓘ |
| isHighlyProteinBound | true ⓘ |
| isLipophilic | true ⓘ |
| isMetabolizedBy |
CYP3A4
ⓘ
amide hydrolysis ⓘ |
| reasonForWithdrawal |
increased risk of depression
ⓘ
increased risk of suicidal ideation ⓘ |
| routeOfAdministration | oral ⓘ |
| targets | cannabinoid receptor type 1 ⓘ |
| usedIn |
preclinical studies of addiction and reward pathways
ⓘ
research on endocannabinoid system ⓘ |
| wasApprovedBy | European Medicines Agency ⓘ |
| wasNotApprovedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| withdrawalYear | 2008 ⓘ |
| withdrawnFromMarketInRegion | European Union ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: rimonabant Description of subject: Rimonabant is a selective cannabinoid CB1 receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
Referenced by (5)
Full triples — surface form annotated when it differs from this entity's canonical label.